Personalized Medicine Highlights from San Antonio Breast Cancer Symposium 2012
December 12, 2012
Personalized Medicine Highlights from San Antonio Breast Cancer Symposium 2012
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Myriad Publishes Data on HRD Test to Detect Response to Platinum-Based Therapy, PARP Inhibitors
October 17, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: NanoString Kicks off Second PAM50 Validation Study; MDxHealth Launches ConfirmMDx
May 16, 2012 / Pharmacogenomics Reporter - Reporting 27 Percent Q3 Jump, Myriad Outlines Three-Pronged Plan for Diversifying Revenue Base
May 2, 2012 / Pharmacogenomics Reporter - Myriad Reports 20 Percent Q1 Revenue Growth, Rising Demand for Colorectal Cancer Test
November 2, 2011 / Pharmacogenomics Reporter - St. Gallen Experts Recommend Oncotype DX for Chemoprediction; Support Breast Cancer Subtyping
July 27, 2011 / Pharmacogenomics Reporter